SynthesisClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2023
Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis.
Synthesis in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed, 2 syntheses or guidelines pooled it, 217 citations in OpenAlex.
- Global status of antimicrobial resistance in clinical Enterococcus faecalis isolates: systematic review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2024Pooled it
- Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis.The Lancet. Microbe · 2023Pooled it
- The agroenvironmental-clinical link of Proteus mirabilis: Genomic epidemiology, clonal relationships, and shared resistance and virulence profiles.Folia microbiologica · 2026Article
- Antimicrobial resistance patterns of Klebsiella pneumoniae clinical isolates in the Qassim region, Saudi Arabia: a surveillance study (2015-2023).BMC infectious diseases · 2026Article
- Shift of antibiotic resistance after the COVID-19 pandemic: results from the INVIFAR Network.JAC-antimicrobial resistance · 2026Article
- Article
- Stratified cumulative antibiograms and antimicrobial resistance trends among hospitalized patients in a Chinese tertiary hospital: a 7-year retrospective study.World journal of microbiology & biotechnology · 2026Article
- Antimicrobial Resistance Trends in Carbapenem-Resistant Enterobacterales in a Saudi Healthcare Setting.Microorganisms · 2026Article
- Epidemiological trends of multidrug-resistant organisms in a tertiary-care pediatric hospital, 2017-2023.Italian journal of pediatrics · 2026Article
- Changes in Antimicrobial Resistance Patterns in Intensive Care Units Following the COVID-19 Pandemic: A 10-Year Retrospective Study from Türkiye.Antibiotics (Basel, Switzerland) · 2026Article
- Temporal trends in Group B Streptococcus colonization, serotype distribution, and antimicrobial resistance among pregnant women in the Brazilian Amazon across the COVID-19 pandemic, 2018-2023.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- A Seven-Year Study of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Antimicrobial Proteins from Limosilactobacillus fermentum GR-9 Inhibit Pathogens and Alleviate Salmonella Paratyphi B Infection in Mice.Probiotics and antimicrobial proteins · 2026Article
- Monitoring the Burden ofAntibiotics (Basel, Switzerland) · 2026Article
- Genomic investigation of the vancomycin-resistant Enterococcus faecium in a tertiary hospital in China.Antimicrobial resistance and infection control · 2026Article
- The Influence of COVID-19 on the Composition and Drug Resistance of Pleural Effusion in Shandong Province.MicrobiologyOpen · 2026Article
- Lessons From the Coronavirus Disease 2019 Pandemic: Implications for Antimicrobial Stewardship for COVID-19 Management.Journal of Korean medical science · 2026Review
- Pioneering strategies for overcoming bacterial drug resistance.Journal of microbiology (Seoul, Korea) · 2026Article
- Patterns of Antibiotic Use in Hospitalized COVID-19 Patients and Association with Secondary Infections and Outcomes.Antibiotics (Basel, Switzerland) · 2026Article
- The Association Between Antibiotic Use and the Incidence of Third-Generation Cephalosporin-Resistance inAntibiotics (Basel, Switzerland) · 2026Article
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 3 countries.
Funding
Abstract
backgroundCOVID-19 and antimicrobial resistance (AMR) are two intersecting global public health crises.
objectiveWe aimed to describe the impact of the COVID-19 pandemic on AMR across health care settings. DATA SOURCE: A search was conducted in December 2021 in WHO COVID-19 Research Database with forward citation searching up to June 2022. STUDY ELIGIBILITY: Studies evaluating the impact of COVID-19 on AMR in any population were included and influencing factors were extracted. Reporting of enhanced infection prevention and control and/or antimicrobial stewardship programs was noted.
methodsPooling was done separately for Gram-negative and Gram-positive organisms. Random-effects meta-analysis was performed.
resultsOf 6036 studies screened, 28 were included and 23 provided sufficient data for meta-analysis. The majority of studies focused on hospital settings (n = 25, 89%). The COVID-19 pandemic was not associated with a change in the incidence density (incidence rate ratio 0.99, 95% CI: 0.67-1.47) or proportion (risk ratio 0.91, 95% CI: 0.55-1.49) of methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci cases. A non-statistically significant increase was noted for resistant Gram-negative organisms (i.e. extended-spectrum beta-lactamase, carbapenem-resistant Enterobacterales, carbapenem or multi-drug resistant or carbapenem-resistant Pseudomonas aeruginosa or Acinetobacter baumannii, incidence rate ratio 1.64, 95% CI: 0.92-2.92; risk ratio 1.08, 95% CI: 0.91-1.29). The absence of reported enhanced infection prevention and control and/or antimicrobial stewardship programs initiatives was associated with an increase in gram-negative AMR (risk ratio 1.11, 95% CI: 1.03-1.20). However, a test for subgroup differences showed no statistically significant difference between the presence and absence of these initiatives (p 0.40).
conclusionThe COVID-19 pandemic may have hastened the emergence and transmission of AMR, particularly for Gram-negative organisms in hospital settings. But there is considerable heterogeneity in both the AMR metrics used and the rate of resistance reported across studies. These findings reinforce the need for strengthened infection prevention, antimicrobial stewardship, and AMR surveillance in the context of the COVID-19 pandemic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.